Comparative Effectiveness of Long-Acting Injectable Versus Oral Antipsychotics in Patients With Schizophrenia Using the Prevalent New User Design and Subgroup Analyses.

IF 2.9 3区医学 Q2 PHARMACOLOGY & PHARMACY

Journal of Clinical Psychopharmacology Pub Date : 2024-04-29 DOI:10.1097/jcp.0000000000001841

Yusuke Okada, Ken Inada, Manabu Akazawa

引用次数: 0

Abstract

We compared the effectiveness of long-acting injectable antipsychotics (LAIs) and oral antipsychotics (OAs) in treating schizophrenia, focusing on whether the benefits of LAIs over OAs are evident even in the prevalent new user design and on effect heterogeneity.

查看原文本刊更多论文

长效注射与口服抗精神病药物在精神分裂症患者中的疗效比较（采用新用户流行设计和亚组分析）。

我们比较了长效注射抗精神病药（LAI）和口服抗精神病药（OA）治疗精神分裂症的疗效，重点关注即使在新用户设计盛行的情况下，长效注射抗精神病药相对于口服抗精神病药的优势是否明显，以及疗效的异质性。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Journal of Clinical Psychopharmacology 医学-精神病学

CiteScore

4.00

自引率

3.40%

发文量

231

审稿时长

4-8 weeks

期刊介绍： Journal of Clinical Psychopharmacology, a leading publication in psychopharmacology, offers a wide range of articles reporting on clinical trials and studies, side effects, drug interactions, overdose management, pharmacogenetics, pharmacokinetics, and psychiatric effects of non-psychiatric drugs. The journal keeps clinician-scientists and trainees up-to-date on the latest clinical developments in psychopharmacologic agents, presenting the extensive coverage needed to keep up with every development in this fast-growing field.